MERS Coronavirus Defeated by AsepticSure

Screenshot-2015-06-29-15.16.53-2

SAN FRANCISCO, Aug. 4, 2014 — Medizone International, Inc. (The Company) (MZEI:QB, MZEI:OB) announces excellent midpoint results from its new antiviral research initiative in collaboration with a world renowned virology institute.asepticsure-product

“Medizone has now completed multiple decontamination runs with well characterized samples of Adenovirus and MERS Coronavirus,” stated Dr Michael Shannon, Medizone’s President. “We are pleased to announce that each run has shown disinfection in a full-scale room setting. Since all of the virology work has been carried out by an internationally respected team of virologists, we have complete confidence that these findings are correct. By destroying both of these viruses, one a non-enveloped virus and the second an enveloped Coronavirus, our understanding of the biological limits for AsepticSure® has been expanded dramatically and of course so has the range of medical applications.”

Shannon continued about the importance of this work: “These new findings should have intriguing implications for the management of new deadly outbreaks world wide. Experts in this field have known for years that bacterial spores and non enveloped viruses are at the top of the biological resistance list for pathogens and we have data by the truck load confirming that AsepticSure can achieve disinfection of these pathogens at very high concentrations. What is most exciting about these recent findings is that highly lethal viruses such as Ebola should be extremely susceptible to AsepticSure disinfection, which may therefore see AsepticSure emerge as a vital component in global efforts to control these new deadly outbreaks.”

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

 

 

For press information on Medizone International, please contact:

John Pentony, Investor Relations
T: (415) 331-0202
E: [email protected]

Gary Hanauer, Media Contact
T: (510) 686-1238
E: [email protected]

For more information, visit:
http://www.medizoneint.com

Email: [email protected]